1Montaho, G., et al., Epidemiology, risk factors, and natural history of hepatocellular carcinoma[J]. Ann N Y Acad Sci, 2002. 963: 13-20.
2Tanaka, S. and S. Arii, Molecular targeted therapies in hepa tocellular carcinoma[J]. Semin Oncol, 2012. 39(4): 486-92.
3Schoenleber, S.J., et al., Prognostic role of vascular endothe lial growth factor in hepatoeellular carcinoma: systematic re view and meta-analysis[J]. Br J Cancer, 2009. 100(9): 1385- 2.
4Yau, T., et al., Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma ?atientswith sorafenib-refractory disease ]J]. Invest New Drugs,2012.30(6): 2384-90.
5Llovet, J.M., et al., Sorafenib in advanced hepatocellular car qnoma[J]. N Engl J Med, 2008. 359(4): 378-90.
6Gauthier, A. and M. Ho, Role of sorafenib in the treatment 3f advanced hepatocellular carcinoma: An update[J]. Hepatol Res,2012. Garcia, J.A. and L.R. Roberts, Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2012. 56(2): 486-7.
7Fob, H.C., et al., Phase 2 trial of linifanib (ABT-869) in mtients with unresectable or metastatic hepatocellular car finoma[J], Cancer, 2013.119(2): 380-7.
8Isu, C., et al., Vandetanib in patients with inoperable hep ttoeellular carcinoma: a phase II, randomized, double-blind, lacebo-controlled study[J]. J Hepatol, 2012. 56(5): 1097- 03.
9Yau, T., et al., Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics [J]. Clin Cancer Res,2011. 17(21):6914-23.
10Bassullu, N., et al., The Predictive and Prognostic Signifi cance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 Expression in Hepatocellular Carcinoma [J]. Hepat Mon, 2012. 12(10 HCC):e7492.
